β-blockers could regenerate infant heart muscle, mitigate effects of congenital heart disease
0 Shares
01
LIVE UPDATES
U.S. FDA Approves Pfizer’s Xeljanz (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
Print this page NEW YORK–(BUSINESS WIRE) September 28, 2020 — Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Xeljanz&#...
Read More- Alabama’s Lagging Vaccination Rates a Concern
- Caring for the world’s wisest people
- FDA Approves Trodelvy (sacituzumab govitecan-hziy) for Previously-Treated Metastatic Triple Negative Breast Cancer
- FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
HighLight
The breakthrough after my breakdown: Flo’s story
September 6th, 2020
More than 2,700 cases of coronavirus in China as death toll climbs to 80
January 27th, 2020
Fragrances can enhance learning during sleep, shows new study
Effortless learning during sleep is the dream of many people. The supportive effect of smells on ...
More Than Half of Doctors Now Part of Healthcare Systems
More than half of US physicians now work for or contract with fewer than 700 healthcare systems a...
NEWS INDEX
Addressing the evidence behind various therapeutic options for adolescents with obesity
Sep 30 2019 As rates of adolescent obesity continue to rise, choice of treatment n...
95% of people think they could develop dementia with age
A global study on attitudes toward dementia has shown that two-thirds of people be...
African American women contend with superwoman persona to cope with racial discrimination
Black women in America often feel pressured to act like Superwoman to cope with th...